These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 33275487)

  • 1. Parsing the Paradox of Myelodysplastic Syndromes.
    Sekeres MA
    J Clin Oncol; 2021 Jan; 39(1):4-6. PubMed ID: 33275487
    [No Abstract]   [Full Text] [Related]  

  • 2. The Yin and Yang of myelodysplastic syndromes and autoimmunity: The paradox of autoimmune disorders responding to therapies specific for MDS.
    Fozza C; La Nasa G; Caocci G
    Crit Rev Oncol Hematol; 2019 Oct; 142():51-57. PubMed ID: 31376677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Excessive proliferation matched by excessive apoptosis in myelodysplastic syndromes: the cause-effect relationship.
    Raza A; Alvi S; Borok RZ; Span L; Parcharidou A; Alston D; Rifkin S; Robin E; Shah R; Gregory SA
    Leuk Lymphoma; 1997 Sep; 27(1-2):111-8. PubMed ID: 9373202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation of the human FMS gene (M-CSF receptor) in myelodysplastic syndromes and acute myeloid leukemia.
    Tobal K; Pagliuca A; Bhatt B; Bailey N; Layton DM; Mufti GJ
    Leukemia; 1990 Jul; 4(7):486-9. PubMed ID: 2142747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differentiation induction therapy of myelodysplastic syndromes.
    Hassan HT; Rees J
    Leuk Res; 1989; 13(7):633-7. PubMed ID: 2668648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of bone marrow microenvironment could change how myelodysplastic syndromes are diagnosed and treated.
    Aanei CM; Catafal LC
    Cytometry A; 2018 Jul; 93(9):916-928. PubMed ID: 30211968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paradox of hope.
    Cohen JV
    J Palliat Med; 2013 Oct; 16(10):1307-8. PubMed ID: 24015817
    [No Abstract]   [Full Text] [Related]  

  • 8. Splicing factor mutations in the myelodysplastic syndromes: target genes and therapeutic approaches.
    Armstrong RN; Steeples V; Singh S; Sanchi A; Boultwood J; Pellagatti A
    Adv Biol Regul; 2018 Jan; 67():13-29. PubMed ID: 28986033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations.
    Girmenia C; Candoni A; Delia M; Latagliata R; Molteni A; Oliva EN; Palumbo GA; Poloni A; Salutari P; Santini V; Voso MT; Musto P
    Blood Rev; 2019 Mar; 34():16-25. PubMed ID: 30448050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Smoking and myelodysplastic syndromes.
    Björk J; Albin M; Mauritzson N; Strömberg U; Johansson B; Hagmar L
    Epidemiology; 2000 May; 11(3):285-91. PubMed ID: 10784245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort study.
    Basiorka AA; McGraw KL; Abbas-Aghababazadeh F; McLemore AF; Vincelette ND; Ward GA; Eksioglu EA; Sallman DA; Ali NA; Padron E; Pinilla-Ibarz J; Komrokji R; Masala E; Santini V; Kosmider O; Fontenay M; Fenaux P; Sokol L; Wei S; Fridley B; List AF
    Lancet Haematol; 2018 Sep; 5(9):e393-e402. PubMed ID: 30072146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.
    Platzbecker U; Germing U; Götze KS; Kiewe P; Mayer K; Chromik J; Radsak M; Wolff T; Zhang X; Laadem A; Sherman ML; Attie KM; Giagounidis A
    Lancet Oncol; 2017 Oct; 18(10):1338-1347. PubMed ID: 28870615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes.
    Cremers EM; Westers TM; Alhan C; Cali C; Visser-Wisselaar HA; Chitu DA; van der Velden VH; Te Marvelde JG; Klein SK; Muus P; Vellenga E; de Greef GE; Legdeur MC; Wijermans PW; Stevens-Kroef MJ; Silva-Coelho PD; Jansen JH; Ossenkoppele GJ; van de Loosdrecht AA;
    Haematologica; 2017 Feb; 102(2):320-326. PubMed ID: 27658438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of cytotoxic T-cell receptor gammadelta T lymphocytes in response to specific stimulation in myelodysplastic syndromes.
    Kiladjian JJ; Visentin G; Viey E; Chevret S; Eclache V; Stirnemann J; Bourhis JH; Chouaib S; Fenaux P; Caignard A
    Haematologica; 2008 Mar; 93(3):381-9. PubMed ID: 18268282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes.
    Suárez L; Vidriales MB; García-Laraña J; Sanz G; Moreno MJ; López A; Barrena S; Martínez R; Tormo M; Palomera L; Lavilla E; López-Berges MC; de Santiago M; de Equiza ME; Miguel JF; Orfao A
    Clin Cancer Res; 2004 Nov; 10(22):7599-606. PubMed ID: 15569991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term bone marrow culture profiles in patients with myelodysplastic syndromes are not explicable by defective apoptosis.
    McMullin MF; Buckley O; Magill MK; Irvine AE
    Leuk Res; 1998 Aug; 22(8):735-40. PubMed ID: 9680101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An association of polymyalgia rheumatica with myelodysplastic syndromes.
    Kohli M; Bennett RM
    J Rheumatol; 1994 Jul; 21(7):1357-9. PubMed ID: 7966085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies on blood and bone marrow findings of myelodysplastic syndromes: evaluation of proposals for classification of myelodysplastic syndromes.
    Yang CL; Li LQ; Chen WJ; Yang TY; Sun YM; Li XY
    Proc Chin Acad Med Sci Peking Union Med Coll; 1988; 3(1):7-11. PubMed ID: 3174618
    [No Abstract]   [Full Text] [Related]  

  • 19. Adverse transfusion reactions in patients with aplastic anaemia or myelodysplastic syndromes.
    Moncharmont P; Quittançon E; Barday G; Benamara A;
    Vox Sang; 2019 May; 114(4):349-354. PubMed ID: 30818416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromes.
    Cluzeau T; McGraw KL; Irvine B; Masala E; Ades L; Basiorka AA; Maciejewski J; Auberger P; Wei S; Fenaux P; Santini V; List A
    Haematologica; 2017 Dec; 102(12):2015-2020. PubMed ID: 28983059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.